Acquisition Momentum As a GeneDx company since 2025, Fabric Genomics has recently transitioned into a broader corporate group, signaling potential for integrated product bundles, cross-sell of AI-driven genomic interpretation, and expanded support services to existing GeneDx customers.

Clinical AI Focus The core offering is an AI-powered decision support platform for clinical laboratories, hospitals, and national programs, presenting sales opportunities to expand adoption in hospitals upgrading genomics workflow efficiency and to partner with labs seeking faster, more accurate genomic interpretations.

Accreditations & Services CLIA and CAP accredited clinical services complement software with interpretation and reporting support, appealing to labs aiming to scale without increasing in-house genetics staff, enabling upsell of managed services alongside software licenses.

Strategic Partnerships Recent and ongoing collaborations with Galatea Bio, PlumCare, Oxford Nanopore, and DNAnexus indicate a channel-ready model for integrating Fabric Genomics into a broader ecosystem, offering co-sell opportunities and joint go-to-market campaigns.

Market Expansion Active development of genetic disease risk assays and integration with PRS algorithms suggests upsell potential to customers pursuing preventive and risk-stratified care, including research partnerships and clinical deployment across newborn screening and hereditary risk assessment programs.